Substantial increase in remdesivir production, allotment to states: Gowda

Union minister Sadananda Gowda on Saturday said that substantial increase has been made in overall production and allotment of remdesivir, used in the treatment of COVID-19, to all states.

This will make India's fight stronger against COVID-19, the Chemicals & Fertilizers Minister said.

In a tweet Gowda said, "After detailed review of state wise allotment of #Remdesivir with @Pharmadept substantial increase has been made in overall production & allotment to all states".

A total of 16 lakh remdesivir vials are being allocated to the states and union territories from April 21to April 30, 2021, Gowda said.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel